Do analysts rate PRFX or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PRFX or GLMD more profitable?

PainReform's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Galmed Pharmaceuticals N/A -35.32% -30.94%

Do analysts prefer PRFX or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PRFX or UPC?

Universe Pharmaceuticals has higher revenue and earnings than PainReform. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PainReform $20K 44.81 -$5.02M -$736.66 N/A Universe Pharmaceuticals $17.86M 1.59 -$3.67M N/A N/A

Is PRFX or UPC more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Universe Pharmaceuticals N/A N/A N/A

Is SXTP or PRFX more profitable?

PainReform has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals -574.91% N/A -131.48% PainReform N/A N/A N/A

Do analysts prefer VCNX or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% PainReform N/A N/A N/A

Do analysts prefer JUNS or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, JUNS or PRFX?

Jupiter Neurosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jupiter Neurosciences $20K 201.74 -$8.65M -$20.30 N/A PainReform $20K 44.81 -$5.02M -$736.66 N/A

Is JUNS or PRFX more profitable?

PainReform's return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -228.63% PainReform N/A N/A N/A

PainReform (PRFX) Competitors

$1.03 -0.17 (-14.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 -0.03 (-2.43%)

As of 07:55 PM Eastern

Compare

PRFX vs. GLMD, UPC, SXTP, VCNX, and JUNS

Should you buy PainReform stock or one of its competitors? PainReform's main competitors and comparable companies include Galmed Pharmaceuticals (GLMD), Universe Pharmaceuticals (UPC), 60 Degrees Pharmaceuticals (SXTP), Vaccinex (VCNX), and Jupiter Neurosciences (JUNS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PainReform compare to Galmed Pharmaceuticals?

PainReform (NASDAQ:PRFX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

37.3% of PainReform shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than PainReform. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for PainReform. PainReform's average media sentiment score of 1.87 beat Galmed Pharmaceuticals' score of 0.30 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Very Positive
Galmed Pharmaceuticals	Neutral

PainReform's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

PainReform has higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	44.81	-$5.02M	-$736.66	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A

PainReform has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Summary

PainReform beats Galmed Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does PainReform compare to Universe Pharmaceuticals?

PainReform (NASDAQ:PRFX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has higher revenue and earnings than PainReform.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	44.81	-$5.02M	-$736.66	N/A
Universe Pharmaceuticals	$17.86M	1.59	-$3.67M	N/A	N/A

37.3% of PainReform shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than PainReform. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 1 mentions for PainReform. PainReform's average media sentiment score of 1.87 beat Universe Pharmaceuticals' score of 1.43 indicating that PainReform is being referred to more favorably in the media.

Company	Overall Sentiment
PainReform	Very Positive
Universe Pharmaceuticals	Positive

PainReform has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Universe Pharmaceuticals	N/A	N/A	N/A

Summary

Universe Pharmaceuticals beats PainReform on 5 of the 8 factors compared between the two stocks.

How does PainReform compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than PainReform. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 1 mentions for PainReform. PainReform's average media sentiment score of 1.87 beat 60 Degrees Pharmaceuticals' score of 0.94 indicating that PainReform is being referred to more favorably in the news media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Positive
PainReform	Very Positive

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, suggesting a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60 Degrees Pharmaceuticals has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market. Comparatively, PainReform has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

PainReform has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
PainReform	N/A	N/A	N/A

PainReform has lower revenue, but higher earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A
PainReform	$20K	44.81	-$5.02M	-$736.66	N/A

Summary

PainReform beats 60 Degrees Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does PainReform compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has lower revenue, but higher earnings than Vaccinex. Vaccinex is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A
PainReform	$20K	44.81	-$5.02M	-$736.66	N/A

In the previous week, Vaccinex and Vaccinex both had 1 articles in the media. PainReform's average media sentiment score of 1.87 beat Vaccinex's score of 0.00 indicating that PainReform is being referred to more favorably in the news media.

Company	Overall Sentiment
Vaccinex	Neutral
PainReform	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
PainReform	N/A	N/A	N/A

Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, PainReform has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Summary

PainReform beats Vaccinex on 6 of the 11 factors compared between the two stocks.

How does PainReform compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

PainReform's return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
PainReform	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

37.3% of PainReform shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Jupiter Neurosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	201.74	-$8.65M	-$20.30	N/A
PainReform	$20K	44.81	-$5.02M	-$736.66	N/A

In the previous week, Jupiter Neurosciences had 2 more articles in the media than PainReform. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 1 mentions for PainReform. PainReform's average media sentiment score of 1.87 beat Jupiter Neurosciences' score of 0.85 indicating that PainReform is being referred to more favorably in the news media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
PainReform	Very Positive

Jupiter Neurosciences has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, PainReform has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

PainReform beats Jupiter Neurosciences on 6 of the 11 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$896K	$11.73B	$6.98B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	0.00	781.47	269.86	25.30
Price / Sales	44.81	750.79	601.81	101.06
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	0.04	10.81	13.08	6.33
Net Income	-$5.02M	$2.77B	$3.45B	$347.70M
7 Day Performance	-0.96%	0.17%	1.12%	1.07%
1 Month Performance	-16.26%	0.35%	1.79%	1.03%
1 Year Performance	-85.49%	161.52%	67.69%	20.77%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.6055 of 5 stars	$1.03 -14.2%	N/A	-83.4%	$896K	$20K	N/A	4	Positive News Gap Down
GLMD Galmed Pharmaceuticals	0.7809 of 5 stars	$0.58 +0.8%	N/A	-63.6%	$3.83M	N/A	N/A	20	Short Interest Increase
UPC Universe Pharmaceuticals	1.367 of 5 stars	$6.16 -12.6%	N/A	+33.4%	$3.45M	$17.86M	N/A	220	Positive News Short Interest Decrease
SXTP 60 Degrees Pharmaceuticals	3.4213 of 5 stars	$1.22 -0.8%	$13.85 +1,035.2%	-78.1%	$3.25M	$1.41M	N/A	3	News Coverage Earnings Report
VCNX Vaccinex	N/A	$1.12 flat	N/A	+34.1%	$2.91M	$388K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. GLMD, UPC, SXTP, VCNX, and JUNS

How does PainReform compare to Galmed Pharmaceuticals?

Summary

How does PainReform compare to Universe Pharmaceuticals?

Summary

How does PainReform compare to 60 Degrees Pharmaceuticals?

Summary

How does PainReform compare to Vaccinex?

Summary

How does PainReform compare to Jupiter Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. GLMD, UPC, SXTP, VCNX, and JUNS

How does PainReform compare to Galmed Pharmaceuticals?

Do analysts rate PRFX or GLMD?

Do insiders & institutionals hold more shares of PRFX or GLMD?

Does the media prefer PRFX or GLMD?

Is PRFX or GLMD more profitable?

Which has stronger earnings & valuation, PRFX or GLMD?

Which has more volatility and risk, PRFX or GLMD?

Summary

How does PainReform compare to Universe Pharmaceuticals?

Do analysts prefer PRFX or UPC?

Which has higher valuation and earnings, PRFX or UPC?

Do insiders & institutionals believe in PRFX or UPC?

Does the media prefer PRFX or UPC?

Which has more volatility & risk, PRFX or UPC?

Is PRFX or UPC more profitable?

Summary

How does PainReform compare to 60 Degrees Pharmaceuticals?

Do institutionals & insiders hold more shares of SXTP or PRFX?

Does the media favor SXTP or PRFX?

Do analysts prefer SXTP or PRFX?

Which has more volatility and risk, SXTP or PRFX?

Is SXTP or PRFX more profitable?

Which has preferable earnings and valuation, SXTP or PRFX?

Summary

How does PainReform compare to Vaccinex?

Do insiders and institutionals hold more shares of VCNX or PRFX?

Do analysts prefer VCNX or PRFX?

Which has better earnings and valuation, VCNX or PRFX?

Does the media refer more to VCNX or PRFX?

Is VCNX or PRFX more profitable?

Which has more risk & volatility, VCNX or PRFX?

Summary

How does PainReform compare to Jupiter Neurosciences?

Is JUNS or PRFX more profitable?

Do analysts prefer JUNS or PRFX?

Do insiders and institutionals believe in JUNS or PRFX?

Which has preferable earnings & valuation, JUNS or PRFX?

Does the media prefer JUNS or PRFX?

Which has more risk and volatility, JUNS or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools